Top 5 Drug Type | Count |
---|---|
Small molecule drug | 17 |
CAR-T | 5 |
Autologous CAR-T | 4 |
Antibody | 2 |
Biological products | 1 |
Target |
Mechanism JAK1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. European Union [+3] |
First Approval Date24 Sep 2020 |
Target |
Mechanism 4-1BB agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MAGEA4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date05 Dec 2023 |
Sponsor / Collaborator |
Start Date22 Sep 2023 |
Sponsor / Collaborator |
Start Date22 Aug 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GLPG-3667 ( TYK2 ) | Dermatomyositis More | Phase 2 |
GLPG-5201 ( 4-1BB x CD19 ) | Chronic Lymphocytic Leukemia More | Phase 2 |
GLPG-5101 ( 4-1BB x CD19 ) | Mantle-Cell Lymphoma More | Phase 1/2 |
GLPG-5301 ( BCMA ) | Multiple Myeloma More | Phase 1/2 |
Ribrecabtagene autoleucel ( BCMA ) | Hematologic Neoplasms More | Phase 1 |